EFFECT ·Filed Sep 16, 2026

KMDA

KAMADA LTD
NEUTRAL
Impact 3/10
Horizonweeks Processed16d 15h ago SEC9999999995-26-002976
IPO/offering going effective
Actionable Insight • Neutral

The shelf effectiveness introduces a standing dilution overhang. Monitor for a prospectus supplement or takedown notice, which would signal an actual offering and likely pressure the stock. The 89% bullish analyst consensus and positive historical performance on KMDA reports suggest the market may absorb a modest offering well, but the overhang alone is a mild headwind.

DirectionNeutral
Confidencehigh
Horizonweeks
Latest settled — T+5d
KMDA ▲ +7.08% at T+5d
NEUTRAL call ✓ call won +7.08% · α vs SPY +4.52% · entry $8.19 → $8.77
Next anchor: T+20d in 11d
Latest observation: T+11 -1.86% FF3 residual α
Entry anchored
Sep 15, 04:00 PM ET
via 1-min bar
T+1d
+5.86%
call +5.86% · α +4.73%
$8.67
settled 16d ago
T+5d
+7.08%
call +7.08% · α +4.52%
$8.77
settled 10d ago
T+20d
—
call — · α —
—
in 11d
T+60d
—
call — · α —
—
in 2mo

Price Chart

Loading chart...

Executive Summary

Kamada Ltd's shelf registration statement on Form F-3 (File No. 333-298814) was declared effective by the SEC on September 15, 2026. This allows the company to offer and sell securities, including common shares, from time to time at its discretion, creating a potential dilution overhang for existing shareholders. The effectiveness itself is a procedural step and does not indicate an immediate offering, but the company now has the flexibility to access capital markets when needed.

Key Facts

  • Kamada Ltd's shelf registration (Form F-3, File No. 333-298814) was declared effective by the SEC on September 15, 2026.
  • The effectiveness allows the company to sell securities, including common shares, at its discretion over time.
  • No specific offering size, pricing, or timing was disclosed in the filing.

Financial Impact

No immediate financial impact; the shelf registration provides optionality for future capital raises of an undisclosed amount.

dilution

Risk Factors

  • Potential dilutive secondary offering at any time without further notice.
  • Market may price in a discount due to the overhang, capping upside.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-002976
Document: 9999999995-26-002976-index.html9999999995-26-002976
Document: 9999999995-26-002976.txt9999999995-26-002976
18 reports for KMDA
Performance horizon
100% Hit rate 8 of 8 directional calls best @ T+20▲ +16.13%Aug 12, 2026
Filters
Rows
Reports for KMDA — sortable, filterable
TypeNow
Sep 16, 2026
16d ago
EFFECT
NEUTRAL ★ 3/10
$8.19 $8.77▲ +7.08%▲ +4.52%$8.20 (+0.12%)
Sep 10, 2026
22d ago
6-K
NEUTRAL ★ 2/10
$7.99 $8.67▲ +8.51%▲ +9.01%$8.20 (+2.63%)
Sep 3, 2026
29d ago
Press Release
NEUTRAL ★ 2/10
$8.54 $8.31▼ −2.69%▼ −1.48%$8.20 (−3.98%)
Sep 3, 2026
29d ago
6-K
NEUTRAL ★ 2/10
$8.54 $8.31▼ −2.69%▼ −1.48%$8.20 (−3.98%)
Aug 17, 2026
6w ago
6-K / PRESS-RELEASE
BULLISH ★ 6/10
$7.76 $8.43▲ +8.63%▲ +9.82%$8.20 (+5.67%)
Aug 12, 2026
7w ago
6-K
BULLISH ★ 6/10
$6.88 $7.89▲ +14.68%▲ +15.12%$8.20 (+19.19%)
Aug 5, 2026
8w ago
6-K
NEUTRAL ★ 2/10
$7.14 $7.26▲ +1.68%▲ +0.47%$8.20 (+14.85%)
Aug 5, 2026
8w ago
6-K
NEUTRAL ★ 2/10
$7.18 $6.88▼ −4.18%▼ −4.53%$8.20 (+14.21%)
Jul 20, 2026
10w ago
6-K
BULLISH ★ 6/10
$7.09 $7.06▼ −0.42%▲ +0.00%$8.20 (+15.66%)
Jul 13, 2026
11w ago
6-K
NEUTRAL ★ 3/10
$7.17 $7.05▼ −1.67%▼ −0.89%$8.20 (+14.37%)
Showing 10 of 18

US Market Status

Market Closed — Opens Mon (36h 14m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access